PCO371 ( DrugBank: PCO-371 )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 235 | Hypoparathyroidism | 1 |
235. Hypoparathyroidism
Clinical trials : 88 / Drugs : 107 - (DrugBank : 24) / Drug target genes : 5 - Drug target pathways : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04209179 (ClinicalTrials.gov) | July 23, 2020 | 28/11/2019 | A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism | A Randomized, Double-Blind, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PCO371 in Patients With Hypoparathyroidism | Hypoparathyroidism | Drug: PCO371;Drug: Placebo | Chugai Pharmaceutical | NULL | Terminated | 18 Years | N/A | All | 5 | Phase 1 | United States;Canada;Hungary |